Kaftrio during pregnancy and after birth
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how the cystic fibrosis medication Kaftrio works during pregnancy and after childbirth. It follows women with cystic fibrosis who are already taking Kaftrio and their newborn babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with cystic fibrosis
- You are currently pregnant
- You are already being treated with Kaftrio
- OR you are a newborn baby of a woman with cystic fibrosis who is taking Kaftrio
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how CFTR modulator medications (used to treat cystic fibrosis) behave in your body during pregnancy and while breastfeeding. The goal is to understand how much of the medication passes into breast milk and whether doses need to be adjusted.
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
This observational study follows people with cystic fibrosis (CF) to understand the long-term impact of CFTR modulator medicines. It may help researchers see how these treatments work over time in real life.
This study tests how starting Trikafta affects exercise ability and breathing in adults with cystic fibrosis. You may be asked to do supervised breathing and exercise tests to see if Trikafta helps your lung function and stamina.
This study tracks the natural course of cystic fibrosis in young children (under 6) and healthy babies over time. It aims to understand how the disease changes in the era of modern treatments, which could help improve care and guide future therapies.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.